- Open
- 31.50
- High
- 33.00
- Low
- 29.00
- Close
- 30.50
- Change
- -1.50 (-4.76%)
- Volume
- 72,839
| 19 Oct 2026 | 07:15:00 | Faron to Report Final Melanoma Survival Data from the MATINS Study at ESMO 2026 |
| 8 Oct 2026 | 07:00:00 | Reminder for investors, analysts and media to register for upcoming R&D Day |
| 6 Oct 2026 | 07:00:00 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board |
| 1 Oct 2026 | 07:00:00 |
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. Its lead product, bexmarilimab, is an investigational humanized antibody designed to target the Clever-1 receptor on macrophages, aiming to reprogram myeloid cell function and enhance immune responses against tumors. Faron conducts clinical trials for bexmarilimab in combination with standard treatments for hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. The company operates globally, seeking to expand the accessibility of immunotherapy for cancer patients.
| 19 Oct 2026 | 07:15:00 | Faron to Report Final Melanoma Survival Data from the MATINS Study at ESMO 2026 |
| 8 Oct 2026 | 07:00:00 | Reminder for investors, analysts and media to register for upcoming R&D Day |
| 6 Oct 2026 | 07:00:00 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board |
| 1 Oct 2026 | 07:00:00 |
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. Its lead product, bexmarilimab, is an investigational humanized antibody designed to target the Clever-1 receptor on macrophages, aiming to reprogram myeloid cell function and enhance immune responses against tumors. Faron conducts clinical trials for bexmarilimab in combination with standard treatments for hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. The company operates globally, seeking to expand the accessibility of immunotherapy for cancer patients.
| 30 Sept 2026 | 07:00:00 | Convertible bond amortization payment deferred by mutual agreement with HCM |
| 26 Aug 2026 |
| Faron targets second-half start for pivotal blood cancer trial after latest investment round |
| 30 Sept 2026 | 07:00:00 | Convertible bond amortization payment deferred by mutual agreement with HCM |
| 26 Aug 2026 |
| Faron targets second-half start for pivotal blood cancer trial after latest investment round |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £213.86bn | +0.1% | |
| £73.95bn | +0.0% | |
| £1.72bn | -0.1% | |
| £104m | -0.1% | |
| £45m | -0.3% | |
FARNFaron Pharmaceuticals OY | £34m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £213.86bn | +0.1% | |
| £73.95bn | +0.0% | |
| £1.72bn | -0.1% | |
| £104m | -0.1% | |
| £45m | -0.3% | |
FARNFaron Pharmaceuticals OY | £34m | -0.8% |
